SGS United Kingdom withdrew GI Dynamics’ CE Mark for its EndoBarrier device.
IQuility is releasing IsolateIBS-IBD, a RNA-based blood test that can help physicians identify irritable bowel syndrome or inflammatory bowel disease.
After discontinuing a drug therapy program that “did not live up to its promise,” Outpost Medicine shifted its focus towards OP-687, an oral therapy for overactive bladder and irritable bowel syndrome.
After announcing positive results from its second phase III trial, Global Data Healthcare Analysts’ Maria Sudul said Ardelyx’s Tenapanor is in line to make a “successful market entry.”
Lumendi completed the first in-human trials of its DiLumen Endolumenal Interventional Platform technology, meeting the study’s primary endpoint.
The U.S. Patent and Trademarks Office granted Immuron a patent for its non-alcoholic steatohepatitis treatment.
More articles on gastroenterology:
GI leader to know: Dr. Donald Gerhardt of Gastrointestinal Associates
Stock market week-in-review for 5 large GI companies — Nov. 13-17
Outpost Medicine pivots to ‘new class of oral therapy’ for IBS — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.